3-Me-PCPy

At Commonwealth level, the current Criminal Code treats analogues of listed controlled drugs and border controlled drugs as controlled drugs. The verified identity of 3-Me-PCPy is 1-[1-(3-methylphenyl)cyclohexyl]pyrrolidine, also called 3-methyl rolicyclidine. Relative to listed phencyclidine, the pyrrolidine ring and methyl substitution fall within the structural-modification routes in section 301.9(1)(c), read with the specified alkyl groups and hydrogen atoms in section 301.9(2); the catch-all in section 301.9(1)(d) also encompasses analogues, chemical derivatives and substances substantially similar in chemical structure. Phencyclidine is listed in Schedule 1 item 221 and Schedule 2 item 181 of the current Regulations, making 3-Me-PCPy a drug analogue for the Commonwealth controlled-drug and border-controlled-drug provisions.

Belgium’s current consolidated Annex IVB lists Me-PCPy as 1-[1-(methylphenyl)cyclohexyl]pyrrolidine; the FDA substance record identifies 3-Me-PCPy as the 3-methylphenyl isomer of that compound. Articles 2(18) and 3 of the Royal Decree bring substances listed in Annex IV within the decree’s scope. Article 6 bars import, export, transport, manufacture, production, possession, sale, supply, delivery, and acquisition without prior authorization, which is limited to scientific or medical purposes.

Mexico requires prior COFEPRIS permits to import or export raw materials or medicines that are or contain narcotics or psychotropics. Annex I lists rolicyclidine and its salts and derivatives in tariff heading 2933.99.99 for both permit regimes; PubChem identifies 3-Me-PCPy as 1-[1-(3-methylphenyl)cyclohexyl]pyrrolidine, a methyl-substituted PCPy derivative. The measure establishes a border-control restriction and does not by itself establish a general possession prohibition, so the narrower restricted_other classification applies.

An official EU technical-regulation document identifies 3-Me-PCPy as 1-[1-(3-methylphenyl)cyclohexyl]pyrrolidine. Poland's current NPS schedule covers arylcyclohexylamine derivatives up to 500 u and expressly permits an alkyl substituent through C6 on the aryl ring and a pyrrolidinyl ring at nitrogen, placing this structure in group VII-NPS. Article 62b of the Act on Counteracting Drug Addiction penalizes unlawful possession of a new psychoactive substance, with higher penalties for a significant quantity. The 2025 and 2026 amending regulations do not alter group VII-NPS.

The Slovenian National Forensic Laboratory identifies 3-Me-PCPy (3-methyl rolicyclidine) in an official analytical report as an NPS and confirms its systematic chemical identity. 3-Me-PCPy is not named in Singapore's current First Schedule. Singapore's Misuse of Drugs Act 1973 uses an effects-based definition covering non-excluded substances capable of stimulating or depressing the central nervous system and affecting mental functioning or emotional state; CNB states that unlisted NPS with that capacity are dealt with as psychoactive substances. Section 11I makes unauthorised possession or consumption an offence, with a defence for possession for a legitimate purpose other than human consumption.

3-Me-PCPy is expressly named in the current annex to Government Regulation No. 11/2025 Coll. as a listed psychoactive substance, with the chemical name 1-[1-(3-methylphenyl)cyclohexyl]pyrrolidine. Section 33j of Act No. 167/1998 Coll. treats manufacture, export, import, distribution, market-directed acquisition and placing on the market as handling, and prohibits that handling except for research. The regulation also covers stereoisomers, salts and esters of listed substances where they can exist.

New Zealand's Misuse of Drugs Act 1975 includes controlled-drug analogues in Class C when their structure is substantially similar to that of a scheduled controlled drug. PubChem records 3-Me-PCPy as 1-[1-(3-methylphenyl)cyclohexyl]pyrrolidine and PCPy as 1-(1-phenylcyclohexyl)pyrrolidine, so the former differs from the scheduled PCPy parent only by a methyl substituent on the phenyl ring and falls within the analogue rule. It is controlled as a Class C analogue rather than through an individual 3-Me-PCPy schedule entry.

3-Me-PCPy is not named as an independent position, but it is covered by the express Schedule I class for 1-phenylcyclohexylamine and its derivatives. PubChem identifies 3-Me-PCPy as 1-[1-(3-methylphenyl)cyclohexyl]pyrrolidine (C17H25N; CID 137332188) and the scheduled parent as 1-phenylcyclohexan-1-amine (C12H17N; CID 31862). Relative to that parent, the product is formed by replacing the two amine hydrogens with one divalent tetramethylene substituent, which closes the pyrrolidine ring, and replacing one phenyl hydrogen with methyl. Those substituents contain five carbon atoms in total, below the parent's twelve-carbon ceiling in Note 6. The current Schedule contains no independent 3-Me-PCPy position, and live State Register of Medicines searches under the common name, English and Russian systematic names, CAS 1622348-63-3, and PubChem CID returned no registration. The current consolidated Resolution is posted by Roszdravnadzor as amended on 11 June 2025; the Schedule I heading states that circulation of its narcotic drugs is prohibited under Russian law. The canonical status is therefore analog_covered. This conclusion uses the expressly derivative-covered 1-phenylcyclohexylamine entry, not the bare rolicyclidine entry.

3-Me-PCPy (3-Me-rolcyclidine), chemically 1-[1-(3-methylphenyl)cyclohexyl]pyrrolidine, falls within the generic arylcyclohexylamine definition in Schedule 2 Part II paragraph 1(d) of the Misuse of Drugs Act 1971. Its pyrrolidyl amino-group replacement and methyl substitution on the phenyl ring are both modifications specified by that provision. It is therefore a Class B controlled drug; unless authorized under the Act, production, supply and possession are unlawful under sections 4 and 5.